利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.019 秒)

    ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
    1.
    发明申请
    ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING 审中-公开
    具有pH依赖性抗原结合的抗体

    公开(公告)号：US20150266974A1

    公开(公告)日：2015-09-24

    申请号：US14677983

    申请日：2015-04-03

    申请人： RINAT NEUROSCIENCE CORP. ,  PFIZER INC.

    发明人： Jaume PONS ,  Jeffrey Raymond CHABOT ,  Javier Fernando CHAPARRO RIGGERS ,  Bruce Charles GOMES ,  Hong LIANG ,  Kapil MAYAWALA ,  Jerome Thomas METTETAL, II ,  Arvind RAJPAL ,  David Louis SHELTON

    IPC分类号： C07K16/42 ,  C07K16/40 ,  C07K16/28

    CPC分类号： C07K16/4291 ,  C07K16/28 ,  C07K16/40 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/21

    摘要： The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g, GMCSF receptor).

    摘要翻译： 本发明涉及与其抗原具有pH依赖性结合的抗体，使得在生理pH（即pH 7.4）下抗原结合的亲和力大于内体pH（即pH6.0或5.5）时的亲和力。 换句话说，pH5.5 / pH7.4或pH6.0 / pH7.4下的KD或koff比大于或等于2,3,4,8,10,16,20,30,40或100 或者更多。 这种pH依赖性抗体优先从内体中的抗原解离。 与抗原为经过抗原介导的清除（例如，PCSK9）的抗原相比，与具有pH 7.4但具有pH依赖性结合的等效KD的抗体相比，可以增加抗体半衰期。 当与抗体（例如IL6）结合时，当抗原经历减少的清除时，具有pH依赖性结合的抗体可降低总抗原半衰期。 具有pH依赖性结合的抗体也可以延长不抗体结合的抗原的降低。 当拮抗通常以高水平存在的靶抗原（例如IgE，DKK1，C5和SOST）时，这可能是重要的。 此外，当抗原是受体时，这种抗体可以增加抗原半衰期，并且当与抗体（例如，GMCSF受体）结合时，该受体具有增加的清除能力。

    ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
    2.
    发明申请
    ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING 审中-公开

    公开(公告)号：US20200024366A1

    公开(公告)日：2020-01-23

    申请号：US16296852

    申请日：2019-03-08

    申请人： Pfizer Inc. ,  RINAT NEUROSCIENCE CORP.

    发明人： Jaume PONS ,  Jeffrey Raymond CHABOT ,  Javier Fernando CHAPARRO RIGGERS ,  Bruce Charles GOMES ,  Hong LIANG ,  KapiI MAYAWALA ,  Jerome Thomas METTETAL, II ,  Arvind RAJPAL ,  David Louis SHELTON

    IPC分类号： C07K16/42 ,  C07K16/40 ,  C07K16/28

    摘要： The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g., GMCSF receptor).

    PC33718E
    3.
    发明申请
    PC33718E 审中-公开

    公开(公告)号：US20160096898A1

    公开(公告)日：2016-04-07

    申请号：US14864750

    申请日：2015-09-24

    申请人： RINAT NEUROSCIENCE CORP. ,  Pfizer Inc.

    发明人： Hong LIANG ,  Yasmina Noubia ABDICHE ,  Javier Fernando CHAPARRO RIGGERS ,  Bruce Charles GOMES ,  Julie Jia Li HAWKINS ,  Jaume PONS ,  Xiayang QIU ,  Pavel STROP ,  Yuli WANG

    IPC分类号： C07K16/40

    CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

    摘要翻译： 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。